Pharmacotherapy of alcohol use disorders

Substance Use and Misuse

Volumn 40, Issue 13-14, 2005, Pages 2001-2020

  Buonopane, Alessandra ^a,d   Petrakis, Ismene L ^a,b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c National Institute of Drug Abuse (NIDA)   (United States)

^d Yale's Addiction Psychiatry Residency   (United States)

Author keywords

"Craving"; Alcohol; Alcohol abuse; Alcohol use related disorders; Dependence; Pharmacotherapy

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ACAMPROSATE; AMITRIPTYLINE; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; DESIPRAMINE; DIAZEPAM; DISULFIRAM; NALMEFENE; NALTREXONE; NEFAZODONE; OLANZAPINE; ONDANSETRON; OPIATE ANTAGONIST; OXCARBAZEPINE; PHENYTOIN; RITANSERIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TIAPRIDE; TOPIRAMATE; VALPROIC ACID; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ANXIETY DISORDER; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOTOXICITY; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONFUSION; DAYTIME SOMNOLENCE; DELIRIUM; DEPRESSION; DERMATITIS; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG FATALITY; DRUG HYPERSENSITIVITY; EUROPE; FATIGUE; FLUSHING; FOOD AND DRUG ADMINISTRATION; GENDER; HEADACHE; HEPATITIS; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MANIA; MENTAL DISEASE; META ANALYSIS; NAUSEA; NEUROBIOLOGY; NONHUMAN; OPTIC NEURITIS; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SEIZURE; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT OUTCOME; UNITED STATES; VOMITING;

ALCOHOL DETERRENTS; ALCOHOLISM; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMORBIDITY; DISULFIRAM; DOPAMINE; DRUG INTERACTIONS; ETHANOL; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MALE; MENTAL DISORDERS; NALTREXONE; NARCOTICS; SEROTONIN; TAURINE;

EID: 31544474581     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826080500294890     Document Type: Review

References (127)

1. Ait-Daoud, N., Johnson, B., et al. (2001). Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: prelimniary clinical evidence. Psychopharmacology 154(1):23-27.
2. Anton, R. F. (1996). Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol & Alcoholism 31(Suppl. 1):43-53.
3. Anton, R. F., Moak, D. H., et al. (1999). Naltrexone and cognitive behavioral therapy for treatment of outpatient alcoholics: result a placebo-controlled trial. American Journal of Psychiatry 156(11):1758-1764.
4. Ashley, O., Marsden, M., et al. (2003). Effectiveness of substance abuse treatment programming for women: a review. Journal of Drug & Alcohol Abuse 29(1):19-53.
5. Beach, C., Mays, D., et al. (1986). Inhibition of elimination of caffeiene by disulfiram in normal subjects and recovering alcoholics. Clinical Pharmacology & Therapeutics 39:265-270.
6. Berlin, R. (1989). Disulfiram hepatoxicity: a consideration of its mechanism and clinical spectrum. Archives of General Psychiatry 24:241-246.
7. Bigelow, G., Stricker, D., et al. (1976). Maintaining disulfiram ingestion among outpatient alcoholic: a security-deposit contingency contracting procedure. Behaviour Research & Therapy 14:378-381.
8. Boileau, I., Assaad, J., et al. (2003). Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49(4):226-231.
9. Brady, K., Myrick, H., et al. (2002). The use of divalproex in alcohol relapse prevention: a pilot study. Drug & Alcohol Dependence 67(3):323-330.
10. Brady, K., Sonne, S., et al. (1995). Sertraline treatment of comorbid post traumatic stress disorder and alcohol dependence. Journal of Clinical Psychiatry 56:502-505.
11. Brienza, R., Stein, M. (2002). Alcohol use disorders in primary care: do gender-specific differnces exist? Journal of General Internal Medicine 17(5):387-397.
12. Brown, C., Kaminksy, M., et al. (1983). Delirium with Phenytoin and Disulfiram Administration. Annals of Emergency Medicine 12:310-313.
13. Carroll, K., Rounsaville, B., et al. (1993). Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic signifigance. Journal of Studies on Alcohol 54(2):199-208.
14. Chick, J. (1999). Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Safety 20(5):427-435.
15. Ciraulo, D. A., Barnhill, J., et al. (1985). Pharmacokinetic interaction of disulfiram and antidepressants. American Journal of Psychiatry 142(11):1373-1374.
16. Cloninger, C. R., Bohman, M., et al. (1981). Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Archives of General Psychiatry 38(8):861-868.
17. Cornelius, J., Salloum, I., et al. (1995). Preliminary report: double-blind, placebo controlled study of fluoxetine in depressed alcoholics. Psychopharmacology Bulletin 31:297-303.
18. Cornelius, J. R., Jarrett, P. J., et al. (1995). Gender effects on the clinical presentation of alcoholics at a psychiatric hospital. Comprehensive Psychiatry 36(6):435-440.
19. Cornelius, J. R., Thase, M. E., et al. (1998). Cocaine use associated with increased suicidal behavior in depressed alcoholics. Addictive Behaviors 23(1):119-121.
20. Croop, D. F. R. S., Faulkner, E. B., et al. (1997). The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Archives of General Psychiatry 54(12):1130-1135.
21. Davies, M. (2003). The Role of GABA receptors in Mediating the Effects of Alcohol in the Central Nervous System. Journal of Psychiatry & Neuroscience 28(4):263-274.
22. Davis, K., Wu, J. (2001). Role of glutamatergic and GABAergic systems in alcoholism. Journal of Biomedical Science 8:7-19.
23. Dawson, D., Grant, B., et al. (1995). Subgroup variations in US drinking patterns: results of the 1992 national longitudinal alcoholic epidemiologic study. Journal of Substance Abuse 7(3):331-344.
24. Dingledine, R., Borges, K., et al. (1999). The glutamate receptor ion channels. Pharmacological Reviews 51(1):7-61.
25. Drake, R., Osher, F., et al. (1996). The Dually Diganosed, in Integrated Mental Health Services.
26. Fisher, C. M. (1989). "Catalonia" due to disulfiram toxicity. Arch Neurol 46(797-804).
27. Frezza, M., Di Padova, C., et al. (1990). High blood alcohol levels in woemen. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. New England Journal of Medicine 322(2):95-99.
28. Fuller, R., Gordis, E. (2001). Naltrexone treatment for alcohol dependence. The New England Journal of Medicine 345(24):1770-1771.
29. Fuller, R., Roth, H., et al. (1983). Compliance with disulfiram treatment of alcoholism. Journal of Chronic Diseases 36:161-170.
30. Fuller, R. K., Branchey, L., et al. (1986). Disulfiram treatment of alcoholism: A veterans administration cooperative study. Journal of American Medical Association 256:1449-1455.
31. Garbutt, J., West, S., et al. (1999). Pharmacological treatment of alcohol dependence, a review of the evidence. Journal of American Medical Association 281:1318-1325.
32. Gardell, L., Whalen, C., et al. (1998). Calproate reduces intake of alcoholic beverage among rats. Behavioral Pharmacology 9(8):683-689.
33. Gastpar, M. T., Bonnet, U., et al. (2002). Lack of efficacy of naltrexone in the prevention of alcohol relapse: resultes from a German multicenter study. Journal of Clinical Psychopharmacology 22(6):592-598.
34. Genazzani, A. R., Nappi, G., et al. (1982). Central deficiency of beta-endorphin in alcohol addicts. Journal of Clinical Endocrinology & Metabolism 55(3):583-586.
35. Gianoulakis, C., de Waele, J. P., et al. (1996). Implication of the endogenous opioid system in excessive ethanol consumption. Alcohol 13(1):19-23.
36. Grant, B. (1997). Prevelance and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the national longitudinal alcohol epidemiologic survey. Journal of Studies on Alcohol 58(5):464-473.
37. Grant, K. A., Colombo, G., et al. (1997). Characterization of the ethanol-like discriminative stimulus effects of 5-HT receptor agonists as a function of ethanol training dose. Psychopharmacology 133(2):133-141.
38. Group, T. C. S. R. (2003). Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE study): a pilot feasibility study. Alcoholism Clinical & Experimental Research 27(7):1123-1131.
39. Harwood, H. (1998). 10th Special Repot to the US Congress on Alcohol and Health, US Department of Health and Human Services.
40. Hodge, C., Chappelle, A., et al. (1996). Dopamine receptors in the medial prefrontal cortex influence ethanol and sucrose-reinforced responding. Alcoholism Clinical & Experimental Research 20:1631-1638.
41. Hoffman, P., Rabe, C., et al. (1989). N-methyl-D-aspartate receptors and ethanol: inhibition of calcium flux and cyclic GMP production. Journal of Neurochemistry 52:1937-1940.
42. Hoffman, P. L. (1995). Glutamate receptors in alcohol withdrawal-induced neurotoxicity. Metabolic Brain Disease 10(1):73-79.
43. Hutchison, K. E., Swift, R., et al. (2001). Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacologia 155(1):27-34.
44. Joca, S., Skalisz, L., et al. (2000). The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. European Neuropsychopharmacology 10(4):223-228.
45. Johnson, B., Ait-Daoud, N., et al. (2003). Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-1685.
46. Johnson, B., Roache, J., et al. (2000). Ondansetron for reduction of drinking among biologically predisposed alcoholic patients - a randomized controlled trial. Journal of American Medical Association 284(8):963-971.
47. Johnson, B. A., Jasinski, D. R., et al. (1996). Ritanserin in the treatment of alcohol dependence-a multi-center clinical trial. Ritanserin study group. Psychopharmacology (Berl) 128(2):206-215.
48. Karam-Hage, M., Bower, K. (2000). Gabapentin treatment for insomnia associated with alcohol dependence. American Journal of Psychiatry 157(1):151.
49. Keane, T. M., Foy, D. W., et al. (1984). Spouse contracting to increase antabuse compliance in alcoholic veterans. Journal of Clinical Psychology 40:340-344.
50. Kessler, R., McGonagle, K., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Archives of General Psychiatry 51:8-19.
51. Kessler, R. C., Nelson, C. B., et al. (1996). The epidemiology of co-occuring addictive and mental disorders: implications of prevention and service utilization. American Journal of Orthopsychiatry 66(1):17-31.
52. Kiefer, F., Jahn, H., et al. (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Archives of General Psychiatry 60(1):92-99.
53. Klingemann, H. K., Sobell, L. C. (2001). Introduction: natural recovery research across substance use. Substance Use & Misuse 36(11):1409-1416.
54. Knapp, C. (1996). Drinking: A Love Story. New York: Dell Publishing.
55. Koob, G. F., Bloom, F. E. (1988). Cellular and molecular mechanisms of drug dependence. Science 242:715-723.
56. Kranzler, H., Burleson, J., et al. (1996). Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism, Clinical & Experimental Research 20:1534-1541.
57. Kranzler, H., Modesto-Lowe, V., et al. (2000). Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22(5):493-503.
58. Kranzler, H., Van Kirk, J. (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism, Clinical and Experimental Research 25:1335-1341.
59. Kranzler, H. R., Burleson, J. A., et al. (1994). Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Archives of General Psychiatry 51(9):720-731.
60. Kranzler, H. R., Burleson, J. A., et al. (1995). Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry 152(3):391-397.
61. Kranzler, H. R., Jaffe, J. H. (1998). Pharmacologic Therapies for Alcoholism. Principles of Addiction Medicine. 2nd ed.
62. Krystal, J., Cramer, J., et al. (2001). Naltrexone in the treatment of alcohol dependence. The New England Journal of Medicine 345(24):1734-1739.
63. Krystal, J. H., Karper, L. P., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51(3):199-214.
64. Krystal, J. H., Petrakis, I. L., et al. (1998). Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Archives of General Psychiatry 55:354-360.
65. Larson, E. W., Olincy, A., et al. (1992). Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcoholism, Clinical & Experimental Research 16(1):125-130.
66. Li, T., Spanagel, R., et al. (2001). Alcohol reinforcement and voluntary ethanol consumption. Alcoholism, Clinical and Experimental Research 25(5):117S-126S.
67. Littleton, J. (1995). Acamprosate in alcohol dependence: how does it work? Addiction 90(9):1179-1188.
68. Loi, C., Day, J., et al. (1989). Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clinical Pharmacology & Therapeutics 45:476-486.
69. Maany, I., Hayashida, M., et al. (1982). Possible toxic interaction between disulfiram and amitriptyline. Archives of General Psychiatry 142:1373-1374.
70. MacLeod, S., Sellers, E., et al. (1978). Interaction of disulfiram with benzodiazepines. Clinical Pharmacology & Therapeutics 24:583-589.
71. Malcolm, R., Myrick, H., et al. (2002). The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. Journal of General Internal Medicine 17(5):349-355.
72. Malec, E., Malec, T., et al. (1996). Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcoholism, Clinical & Experimental Research 20(2):307-312.
73. Mann, K., Batra, A., et al. (1992). Do women develop alcoholic brain damage more readily than men? Alcoholism, Clinical and Experimental Research 16(6):1052-1056.
74. Mark, T., Kranzler, H. R., et al. (2003). Physicians' opinions about medications to treat alcoholism. Addiction 98:617-626.
75. Marra, D., Warot, D., et al. (2002). Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcoholism, Clinical and Experimental Research 26(10):1545-1552.
76. Mason, B. (2000). Acamprosate: new preclinical and clinical findings. Denver, CO: 2000 Scientific Meeting of the Research Society on Alcoholism.
77. Mason, B. (2001). Treatment of alcohol-dependent outpatients wiht acamprosate: a clinical review. Journal of Clinical Psychiatry 62(20):42-48.
78. Mason, B. J., Ritvo, E. C., et al. (1994). A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcoholism, Clinical & Experimental Research 18(5):1162-1167.
79. Mason, N. (1989). Disulfiram-induced hepatitis: case report and review of the literature. DICP 23:872-875.
80. Maxwell, S., Shinderman, M. S. (2000). Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. Journal of Addictive Diseases 19(3):61-69.
81. McCance-Katz, E. F., Kosten, T. R., and Jatlow, P. (1998). Disulfiram effects on acute cocaine administration. Drugs & Alcohol Dependence 52(1):27-39.
82. Mezey, E., Kolman, C., et al. (1988). Alcohol and dietary intake in the development of chronic pancreatitis and liver disease in alcoholism. American Journal of Clinical Nutrition 48(1):148-151.
83. Morris, P. L., Hopwood, M., et al. (2001). Naltrexone for alcohol dependence: a randomized controlled trial, [comment]. Addiction. 96(11):1565-1573.
84. Mueller, T. I., Stout, R. L., et al. (1997). A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcoholism, Clinical and Experimental Research 21(1):86-92.
85. Mueser, K., Noordsy, D., et al. (2003). Disulfiram treatment for alcoholism in severe mental illness. The American Journal on Addictions 12:242-252.
86. Myrick, H., Brady, K. T., et al. (2001). New developments in the pharmacotherapy of alcohol dependence. American Journal of Addictions 10(Suppl:):16-23.
87. Namkoong, K., BO, L., et al. (2003). Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol & Alcoholism 38(2):135-141.
88. Nasr, S. (2002). Oxcarbazepine for mood disorders. American Journal of Psychiatry 159(10):1793.
89. O'Farrell, T. J., Bayog, R. D. (1986). Antabuse contracts for married alcoholics and their spouses: a method to maintain antabuse ingestion and decrease conflict about drinking. Journal of Substance Abuse Treatment 3:1-8.
90. O'Malley, S. S. (1995). Strategies to maximize the efficacy of naltrexone for alcohol dependence. NIDA Research Monograph 150:53-64.
91. O'Malley, S. S., Jaffe, A. J., et al. (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49(11):881-887.
92. O'Reilly, R. (1981). Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clinical Pharmacology & Therapeutics 29:332-336.
93. Paille, F. M., Guelfi, J. D., et al. (1995). Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol & Alcoholism 30(2):239-247.
94. Pelc, I., Ansoms, C., et al. (2002). The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcoholism, Clinical and Experimental Research 26(10):1529-1538.
95. Pelc, I., Verbanck, P., et al. (1997). Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 171:73-77.
96. Petrakis, I., Trevisan, L., et al. (1999). CSF monoamine metabolite and beta-endorphin levels in recently detoxified alcoholics and healthy controls: prediction of alcohol cue-induced craving. Alcoholism, Clinical and Experimental Research 23(8):1336-1341.
97. Petrakis, I. L., Carroll, K. M., et al. (2000). Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95(2):219-228.
98. Petrakis, I. L., Leslie, D., et al. (2003). Use of naltrexone in the treatment of alcoholism nationally in the department of veterans affairs. Alcoholism, Clinical and Experimental Research 27(11):1780-1784.
99. Petrakis, I. L., O'Malley, S., et al. (2004). Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 172:291-297.
100. Petrakis, I. L., Trevisan, L., et al. (2001). Effect of tryptophan depletion on alcohol cue-induced craving in abstinent alcoholic patients. Alcoholism, Clinical and Experimental Research 25(8):1151-1155.
101. Pettinati, H., Oslin, D., et al. (2000). Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. The International Journal of Neuropsychiatric Medicine 5(2):33-46.
102. Pettinati, H. M. (2001). The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. Journal of Clinical Psychiatry 62 Suppl(20):26-31.
103. Pettinati, H. M., Volpicelli, J. R., et al. (2000). Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism, Clinical & Experimental Research 24(7):1041-1049.
104. Poldrugo, F. (1997). Acamprosate treatment in a long-term community based alcohol rehabilitation programme. Addiction 92(11):1537-1546.
105. Regier, D. A., Farmer, M. E., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study [see comments]. Journal of American Medical Association 264(19):2511-2518.
106. Roussaux, J. P., Hers, D., et al. (1996). [Does acamprosate deminish the appetite for alcohol in weaned alcoholics?]. Journal de Pharmacie de Belgique 51(2):65-68.
107. Roy, A., Linnoila, M. (1989). CSF studies on alcoholism and related behaviours. Progress in Neuro-Psychopharmacology & Biological Psychiatry 13(3-4):505-511.
108. Salloum, I., Cornelius, J., et al. (1998). Naltrexone utility in depressed alcoholics. Psychopharmacology 34(1):111-115.
109. SAMSHSA (2002). National survey on drug use and health. Rockville, MD: Substance Abuse and Mental Health Services Administration.
110. Sass, H., Soyka, M., et al. (1996). Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence [published erratum appears in Arch Gen Psychiatry 1996 Dec;53(12):1097]. Arch Gen Psychiatry 53(8):673-680.
111. Schutz, C., Soyka, M. (2000). Dextromethorphan challenge in alcohol-dependent patients and controls (letter, comment). Archives of General Psychiatry 57:291-292.
112. Sellers, E. M., Toneatto, T., et al. (1994). Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcoholism, Clinical and Experimental Research 18(4):879-885.
113. Shaw, G., Majumdar, S., et al. (1987). Tiapride in the long-term management of alcoholics of anxious or depressive temperament. British Journal of Psychiatry 150:164-168.
114. Thomas, C., Wallack, S., et al. (2003). Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 24:1-11.
115. Tornabene, V. (1974). Narcotic withdrawal syndrome caused by naltrexone. Annals of Internal Medicine 81(6):785-787.
116. Tsai, G., Gastfriend, D. R., et al. (1995). The glutamatergic basis of human alcoholism [see comments]. American Journal of Psychiatry 152(3):332-340.
117. Upton, R. (1991). Pharmacokinetic interactions between theophylline and other medication (part 1). Clinical Pharmacokinetics 20:66-80.
118. Urbano-Marquez, A., Estruch, R., et al. (1995). The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 274(2):149-154.
119. Volkow, N. D., Fowler, J., et al. (2002). Role of dopamine, the frontal cortex, and memory circuits in drug addiction: insight from imaging studies. Neurobiology of Learning & Memory 78(3):610-624.
120. Volpicelli, J. R., Alterman, A., et al. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry. 49(11):876-880.
121. Volpicelli, J. R., Alterman, A. I., et al. (1992). Naltrexone in the treatment of alcohol dependence [see comments]. Archives of General Psychiatry 49(11):876-880.
122. Volpicelli, J. R., Rhines, K. C., et al. (1997). Naltrexone and alcohol dependence. Role of subject compliance [see comments]. Archives of General Psychiatry 54(8):737-742.
123. Weinstein, A., Feldtkeller, B., et al. (2003). A pilot study on the effects of treatment with acomprosate on craving for alcohol in alcohol dependent patients. Addiction Biology 8(2):229-232.
124. Weiss, F., Lorang, M., et al. (1993). Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. Journal of Pharmacology and Experimental Theraputics 267:250-258.
125. Whitworth, A. B., Fischer, F., et al. (1996). Comparison of acamprosate and placebo in long-term treatment of alcohol dependence [see comments]. Lancet 347(9013):1438-1442.
126. Wilsnack, S., Wilsnack, R. (1991). Epidemiology of Women's Drinking. Journal of Substance Abuse 3(2):133-157.
127. Ziedonis, D., Brady, K. (1997). Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Medical Clinics of North America 81(4):1017-1036.